Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations

NCT02283177 is registered in ClinicalTrials.gov with Arog Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02283177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations
Lead sponsor
Arog Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
December 31, 2019
Enrollment
44 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed aml with flt3 activating mutations